Dapagliflozin for heart failure with preserved pumping strength
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if dapagliflozin helps reduce fat around the heart in people with a type of heart failure where the heart pumps normally but is stiff. It might improve symptoms and overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have heart failure with preserved ejection fraction (your heart's pumping strength is at least 50%).
- You have a body mass index (BMI) over 27, which is considered overweight.
- You do not have type 1 diabetes.
- You do not have severe kidney or liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial tests if dapagliflozin, a medication usually used for diabetes, can help people with acute heart failure recover heart function. If you are in the hospital for heart failure, this study will check if the drug improves how your heart squeezes.
This trial tests whether adding dapagliflozin (a medication that helps protect the heart and kidneys) helps people with heart failure who are also on peritoneal dialysis. It may offer extra support for your heart and kidney health.
This study tests how a medication called DAPA (an SGLT2 inhibitor) affects the body in people with heart failure (with or without type 2 diabetes), or in some people with type 2 diabetes only. It may help researchers understand who could benefit most and what changes happen in the heart, using specialized heart imaging.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This study tests whether a medication called dapagliflozin (a pill for heart failure) can help people with a Fontan circulation who feel short of breath. It aims to improve symptoms and quality of life.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.